Leukemia ikabije ya Lymphoblastic (T-ALL)-08

Yesheng wo muri Fujian yagize ati: "Iyo mba nzi ibya CAR-T muri BIOOCUS Medical Group, nari kuza kare."

Muri Nzeri 2017, Yesheng yagize uduheri mu maso, twagiye dukwirakwira buhoro buhoro ndetse tuvamo uduce duto. Ku ya 28 Gashyantare 2018, isuzuma ry’umusemburo w’amagufwa ryemeje ko hari "leukemia y’uturemangingo twa T" nyuma yo guhabwa imiti myinshi, ndetse hagasuzumwa ko nta ndwara ihari rimwe na rimwe. Imiti yose yahagaritswe muri Kamena 2019.

Muri Gicurasi 2021, Yesheng yagaragayemo uduce twinshi mu gace k'umunwa no mu gifu ndetse no mu mitsi yo mu ijosi yagutse. Isuzuma ry’umusemburo wo mu igufwa ryemeje ko kanseri y’amaraso yongeye kugaruka burundu. Ku ya 28 Gicurasi, Yesheng yoherejwe mu Ishami rya Kabiri ry’Ubumenyi bw’Amaraso kugira ngo yemererwe kwakirwa. Nyuma y’ibizamini birambuye, isuzuma ryavuguruwe rihinduka "Leukemia ikabije (T/myeloid biphenotypic)."

Inzira imwe yo gukoresha imiti ya chimiotherapie ntiyatumye habaho koroherwa mu musemburo w'amagufwa. Ku ya 27 Nyakanga, Yesheng yahawe CD7 CAR-T cells, hakurikiraho imiti ya chimiotherapie ivanze na autologous CD7 CAR-T cells. Nyuma y'iminsi cumi n'itanu, isuzuma ry'umusemburo w'amagufwa ryagaragaje ko nta ndwara yari isigaye, hamwe n'uburyo bwo kuvura cytokine release syndrome (CRS) yo mu cyiciro cya mbere kandi nta ngaruka mbi zo mu mitsi yo hagati.